Drug profile · INN
tazemetostat hydrobromide
TAZVERIK
tazemetostat hydrobromide (TAZVERIK) is a histone-lysine n-methyltransferase ezh2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — tazemetostat hydrobromide
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
tazemetostat hydrobromide (TAZVERIK) is a histone-lysine n-methyltransferase ezh2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Histone-lysine N-methyltransferase EZH2 inhibitor
Primary target: Histone-lysine N-methyltransferase EZH2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Pipeline programs
Frequently asked questions
What is tazemetostat hydrobromide?
tazemetostat hydrobromide (TAZVERIK) is a histone-lysine n-methyltransferase ezh2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for tazemetostat hydrobromide?
TAZVERIK is a marketed brand name for tazemetostat hydrobromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tazemetostat hydrobromide?
tazemetostat hydrobromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.